A Phase 1, Randomized, Double-blind, Third-party Open, Placebo-controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single And Multiple Intravenous And Subcutaneous Doses Of Pf-06817024 In Healthy Subjects Who May Be Mildly Atopic And Of Single Doses Of Pf-06817024 In Patients With Chronic Rhinosinusitis With Nasal Polyps

Trial Profile

A Phase 1, Randomized, Double-blind, Third-party Open, Placebo-controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single And Multiple Intravenous And Subcutaneous Doses Of Pf-06817024 In Healthy Subjects Who May Be Mildly Atopic And Of Single Doses Of Pf-06817024 In Patients With Chronic Rhinosinusitis With Nasal Polyps

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs PF 06817024 (Primary)
  • Indications Rhinosinusitis
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 19 Jun 2017 Planned number of patients changed from 115 to 99.
    • 19 Jun 2017 Planned End Date changed from 1 Jun 2019 to 8 Nov 2019.
    • 19 Jun 2017 Planned primary completion date changed from 1 Jun 2019 to 8 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top